NorthStrive Biosciences Files Two U.S. Patents for EL-22, EL-32 to Preserve Muscle in GLP-1 Therapies
ELAB•NorthStrive Biosciences filed U.S. patent applications nos. 19/709,895 and 19/709,950 for EL-22 and EL-32, targeting lean muscle preservation during GLP-1 and next-generation obesity therapies. Applications claim Myo-2 peptide constructs, Lactobacillus paracasei platforms, and combination regimens with apelin or ursolic acid across multiple delivery formats.
1. Patent Applications
On June 18, NorthStrive Biosciences filed U.S. patent applications nos. 19/709,895 (EL-22) and 19/709,950 (EL-32) for preserving lean muscle mass in human patients undergoing obesity-related weight loss, including treatments with GLP-1 receptor agonists and dual/triple incretin therapies.
2. Technological Approaches
The EL-22 application claims Myo-2 peptide constructs, fusion proteins combining myostatin mature protein with Myo-2 peptides, and co-administration with apelin or ursolic acid. The EL-32 filing covers transformed microorganisms such as Lactobacillus paracasei displaying myostatin and activin A proteins, across oral, injectable, nasal, and topical formats.
3. Strategic Expansion and Market Opportunity
This filing represents a strategic shift from animal health to human-use IP in the rapidly growing GLP-1 and obesity treatment market. The company aims to address lean muscle preservation during weight loss, creating a complementary offering to leading therapies like semaglutide and tirzepatide.
